Supriya Lifescience - Public Comps and Valuation Multiples

Supriya Lifescience Overview

About Supriya Lifescience

Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.

Founded

2008

HQ

Employees

515

Website

supriyalifescience.com

Sectors

Small Molecules
BioTech
DeepTech

Financials

LTM Revenue $84.6M

LTM EBITDA $30.1M

EV

$662M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Supriya Lifescience Financials

As of September 2025, Supriya Lifescience reported last 12-month revenue of $84.6M and EBITDA of $30.1M.

In the same period, Supriya Lifescience generated $61.9M in LTM gross profit and $21.4M in net income.

See Supriya Lifescience valuation multiples based on analyst estimates

Supriya Lifescience P&L

In the most recent fiscal year, Supriya Lifescience reported revenue of $76.6M and EBITDA of $30.4M.

Supriya Lifescience expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Supriya Lifescience valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$84.6M	XXX	$76.6M	XXX	XXX	XXX
Gross Profit	$61.9M	XXX	$44.4M	XXX	XXX	XXX
Gross Margin	73%	XXX	58%	XXX	XXX	XXX
EBITDA	$30.1M	XXX	$30.4M	XXX	XXX	XXX
EBITDA Margin	36%	XXX	40%	XXX	XXX	XXX
EBIT	$27.4M	XXX	$26.6M	XXX	XXX	XXX
EBIT Margin	32%	XXX	35%	XXX	XXX	XXX
Net Profit	$21.4M	XXX	$21.2M	XXX	XXX	XXX
Net Margin	25%	XXX	28%	XXX	XXX	XXX
Net Debt	XXX	XXX	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Supriya Lifescience including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $84.6M. EBITDA for the last twelve months was $30.1M. In the most recent fiscal year, Supriya Lifescience achieved $76.6M in revenue and $30.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$84.6M	Analyst estimates available to subscribers	$76.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$61.9M	Analyst estimates available to subscribers	$44.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	73.1% gross margin	Analyst estimates available to subscribers	57.9% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$30.1M	Analyst estimates available to subscribers	$30.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	35.6% EBITDA margin	Analyst estimates available to subscribers	39.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$27.4M	Analyst estimates available to subscribers	$26.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	32.4% EBIT margin	Analyst estimates available to subscribers	34.7% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$21.4M	Analyst estimates available to subscribers	$21.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	25.2% net profit margin	Analyst estimates available to subscribers	27.7% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	n/a	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Supriya Lifescience

This financial data table provides comprehensive performance metrics for Supriya Lifescience, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Supriya Lifescience generated $84.6M in revenue over the last twelve months.
The company achieved $30.1M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $61.9M.
Net income over the last twelve months reached $21.4M.

Fiscal Year Performance

In the most recent fiscal year, Supriya Lifescience reported $76.6M in total revenue.
Fiscal year EBITDA was $30.4M.
The company maintained a gross profit margin of 57.9% in the most recent fiscal year.
EBITDA margin for the fiscal year was 39.6%.
Net profit margin reached 27.7% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Supriya Lifescience. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Supriya Lifescience Stock Performance

Supriya Lifescience has current market cap of INR 59.5B (or $671M), and EV of INR 58.7B (or $662M).

Market Cap Evolution

Supriya Lifescience Stock Data

As of October 17, 2025, Supriya Lifescience's stock price is INR 739 (or $8).

See Supriya Lifescience trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$662M	$671M	XXX	XXX	XXX	XXX	$0.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Supriya Lifescience Valuation Multiples

Supriya Lifescience's trades at 9.0x EV/Revenue multiple, and 23.6x EV/EBITDA.

See valuation multiples for Supriya Lifescience and 15K+ public comps

Supriya Lifescience Financial Valuation Multiples

As of October 17, 2025, Supriya Lifescience has market cap of $671M and EV of $662M.

Equity research analysts estimate Supriya Lifescience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Supriya Lifescience has a P/E ratio of 31.4x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$671M	XXX	$671M	XXX	XXX	XXX
EV (current)	$662M	XXX	$662M	XXX	XXX	XXX
EV/Revenue	7.8x	XXX	9.0x	XXX	XXX	XXX
EV/EBITDA	22.0x	XXX	23.6x	XXX	XXX	XXX
EV/EBIT	24.2x	XXX	27.1x	XXX	XXX	XXX
EV/Gross Profit	10.7x	XXX	n/a	XXX	XXX	XXX
P/E	31.4x	XXX	34.8x	XXX	XXX	XXX
EV/FCF	20.5x	XXX	-923.1x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Supriya Lifescience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Supriya Lifescience Margins & Growth Rates

Supriya Lifescience's last 12 month revenue growth is 20%

Supriya Lifescience's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $34K for the same period.

Supriya Lifescience's rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Supriya Lifescience's rule of X is 85% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Supriya Lifescience and other 15K+ public comps

Supriya Lifescience Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	20%	XXX	20%	XXX	XXX	XXX
EBITDA Margin	36%	XXX	38%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	14%	XXX	XXX	XXX
Rule of 40	58%	XXX	58%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	85%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$34K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	5%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	23%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial